BioNotebook: Vertex/BioAxone and four other deals; three VC updates, three public offerings
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals said in its annual report filed recently with the US Securities and Exchange Commission (SEC) that it has licensed VX-210 (formerly Cethrin) for spinal cord injuries from BioAxone Biosciences for $10m up front and up to $90m in development and regulatory milestone payments and license continuation fees.
You may also be interested in...
Finance Watch: Government Grants Galore And Other New Funding Sources
While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.